An investigation on behalf of investors in Gemphire Therapeutics Inc. (NASDAQ: GEMP) shares over potential wrongdoing at Gemphire Therapeutics Inc. was announced.
San Diego, CA -- (SBWIRE) -- 10/17/2018 -- An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Gemphire Therapeutics Inc.
Investors who purchased shares of Gemphire Therapeutics Inc. (NASDAQ: GEMP) have certain options and should contact the Shareholders Foundation at firstname.lastname@example.org or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain Gemphire Therapeutics directors breached their fiduciary duties and caused damage to the company and its shareholders.
Livonia, MI based Gemphire Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia and non-alcoholic steatohepatitis (NASH).
On August 4, 2016, Gemphire Therapeutics Inc., issued materials related to its August 2016 Initial Public Offering. In the Prospectus related to the IPO, Gemphire Therapeutics Inc., stated that the FDA had "determined that [product candidate] gemcabene was a potential peroxisome proliferator-activated receptor (PPAR) agonist. As a result, the FDA imposed a partial clinical hold, which restricts us from conducting clinical trials for gemcabene beyond six months in duration, and requires us to conduct two-year rat and mouse carcinogenicity studies before conducting trials of longer than six months."
Shares of Gemphire Therapeutics Inc. (NASDAQ: GEMP) reached as high as $1.27 per share in July 2017.
Then on August 6, 2018, Gemphire Therapeutics Inc., announced that the FDA would require additional data from the Company in order to lift the clinical hold on gemcabene, and that the "End of Phase 2 meeting, and consequently the initiation of Phase 3 trials investigating gemcabene in dyslipidemia indications and long-term safety exposure trials needed for registration, will not take place until the partial hold has been lifted."
Then on August 10, 2018, Gemphire Therapeutics Inc., issued a press release announcing the termination of the phase 2a clinical trial of gemcabene in pediatric non-alcoholic fatty liver disease, citing unexpected problems: "The increase in liver fat was deemed an unexpected problem by the trial investigator because it was an unexpected consistent pattern of worsening of the disease… which the investigator believed was likely due to the drug."
Then on August 13, 2018, Gemphire Therapeutics Inc., announced that the development of Gemphire would be paused.
Those who purchased shares of Gemphire Therapeutics Inc. (NASDAQ: GEMP) have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North - Suite 423
92108 San Diego
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, , which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigation, and/or settlements are not filed/reached and/or related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
For more information on this press release visit:
Media Relations Contact
Email: Click to Email Michael Daniels